EyeGene,Inc Korea approves revised Phase 2/3 trial plan for EGMCV4 meningococcal vaccine
AI summary · Not investment advice
Regulators approved a revised Phase 2/3 trial plan for EGMCV4, a meningococcal vaccine from Egene, in Korea on November 12, 2026.
Commentary
AI commentary · Not investment advice
What happened
Aigen received approval from Korea's Ministry of Food and Drug Safety (MFDS) to change the plan for its phase 2/3 trial of EGMCV4, a 4-valent meningococcal vaccine. The vaccine aims to prevent invasive meningococcal disease caused by groups A, C, W-135 and Y.
In the company's terms
The trial runs in South Korea at multiple sites, including Eunpyeong St. Mary's Hospital of the Catholic University of Korea. Part 1 is phase 2 with a target of 125 participants. Part 2 is phase 3 with a target of 998 participants, split into Cohort A with 730 and Cohort B with 268. Cohort B has 230 in the test group and 38 in the control group, and it assesses safety only.
What changes for shareholders
The change follows an MFDS request for revisions. The trial title now says double-blind, meaning neither participants nor evaluators know who gets which treatment. To keep Cohort B double-blind, the number of control participants was increased.
The trial period is 30 months from the approval date of the institutional review board. It can be extended depending on how long recruitment takes. The expected end date is 2027.12.31.
Earlier filings of the same type
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.102026.11.10 | Nov 10, 2026 |
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
E